Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMMB Chemomab Therapeutics	$0.89 +0.6%	$1.09	$0.87 ▼ $2.55	$16.78M	0.52	114,253 shs	302,411 shs
OGEN Oragenics	$1.11 +2.8%	$1.86	$1.03 ▼ $40.80	$4.46M	0.65	326,599 shs	57,164 shs
PMN Promis Neurosciences	$0.54 -2.4%	$0.59	$0.38 ▼ $1.59	$27.76M	-0.04	1.07 million shs	334,222 shs
SYBX Synlogic	$1.46 +4.3%	$1.38	$0.90 ▼ $1.96	$17.08M	0.52	53,691 shs	10,579 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMMB Chemomab Therapeutics	+0.56%	-4.30%	-19.09%	-34.80%	-27.05%
OGEN Oragenics	+2.78%	-3.48%	-22.92%	-80.53%	-96.08%
PMN Promis Neurosciences	-2.39%	-13.14%	-39.10%	+6.12%	-56.43%
SYBX Synlogic	+4.29%	-1.35%	-8.75%	+29.20%	-0.68%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CMMB Chemomab Therapeutics	3.4857 of 5 stars	3.5	5.0	0.0	0.0	3.3	1.7	0.6
OGEN Oragenics	0.1216 of 5 stars	0.0	4.0	0.0	0.0	0.0	0.0	0.0
PMN Promis Neurosciences	2.3945 of 5 stars	3.5	5.0	0.0	0.0	0.0	0.8	0.6
SYBX Synlogic	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMMB Chemomab Therapeutics	3.00	Buy	$8.50	855.06% Upside
OGEN Oragenics	0.00	N/A	N/A	N/A
PMN Promis Neurosciences	3.00	Buy	$4.33	708.61% Upside
SYBX Synlogic	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest OGEN, SYBX, PMN, and CMMB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/21/2025	PMN Promis Neurosciences	Leede Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy
7/14/2025	PMN Promis Neurosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00
7/14/2025	PMN Promis Neurosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	$0.51 per share	N/A
OGEN Oragenics	N/A	N/A	N/A	N/A	$0.61 per share	N/A
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	($0.01) per share	N/A
SYBX Synlogic	$10K	1,708.20	N/A	N/A	$1.08 per share	1.35

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMMB Chemomab Therapeutics	-$13.94M	-$0.59	N/A	N/A	N/A	N/A	-94.71%	-76.53%	N/A
OGEN Oragenics	-$20.66M	-$21.42	N/A	∞	N/A	N/A	-2,087.95%	-486.56%	N/A
PMN Promis Neurosciences	$2.78M	-$0.21	N/A	N/A	N/A	N/A	-266.69%	-131.59%	N/A
SYBX Synlogic	-$23.36M	-$2.51	N/A	N/A	N/A	N/A	-8.09%	-5.50%	11/11/2025 (Estimated)

Latest OGEN, SYBX, PMN, and CMMB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	CMMB Chemomab Therapeutics	-$0.20	-$0.09	+$0.11	-$0.09	N/A	N/A
8/13/2025	Q2 2025	PMN Promis Neurosciences	-$0.22	-$0.29	-$0.07	-$0.29	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	N/A
OGEN Oragenics	N/A	N/A	N/A	N/A	N/A
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	N/A
SYBX Synlogic	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMMB Chemomab Therapeutics	N/A	7.42	5.33
OGEN Oragenics	N/A	1.93	1.93
PMN Promis Neurosciences	N/A	0.97	0.97
SYBX Synlogic	N/A	3.63	3.63

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMMB Chemomab Therapeutics	46.05%
OGEN Oragenics	18.71%
PMN Promis Neurosciences	50.13%
SYBX Synlogic	63.40%

Insider Ownership

Company	Insider Ownership
CMMB Chemomab Therapeutics	11.91%
OGEN Oragenics	4.90%
PMN Promis Neurosciences	6.11%
SYBX Synlogic	3.02%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMMB Chemomab Therapeutics	20	18.86 million	16.61 million	Not Optionable
OGEN Oragenics	5	4.13 million	10.98 million	N/A
PMN Promis Neurosciences	5	51.81 million	48.64 million	Not Optionable
SYBX Synlogic	80	11.70 million	11.35 million	Optionable

OGEN, SYBX, PMN, and CMMB Headlines

Recent News About These Companies

Synlogic, Inc. (SYBX) Latest Stock News & Headlines - Yahoo Finance

June 28, 2025 | finance.yahoo.com

Synlogic's executive sells shares worth $2,802

February 5, 2025 | msn.com

Synlogic Reports Q3 2024 Financial Outcomes

November 14, 2024 | markets.businessinsider.com

Synlogic, Inc.: Synlogic Reports Third Quarter 2024 Financial Results

November 13, 2024 | finanznachrichten.de

Synlogic Reports Third Quarter 2024 Financial Results

November 12, 2024 | globenewswire.com

Synlogic preps phenylketonuria drug for phase 3 after mid-stage win

November 6, 2024 | pharmaphorum.comP

Synlogic, Inc. (0A8U.L)

August 24, 2024 | nz.finance.yahoo.com

MIN.SG,0P0001I7V6,0 (MIN.SG)

August 16, 2024 | nz.finance.yahoo.com

Maintaining Hold on Synlogic Amid Strategic Reassessment and Financial Uncertainty

August 14, 2024 | markets.businessinsider.com

Synlogic, Inc.: Synlogic Reports Second Quarter 2024 Financial Results

August 8, 2024 | finanznachrichten.de

SYBX Stock Earnings: Synlogic Beats EPS for Q2 2024

August 8, 2024 | investorplace.com

Synlogic Reports Second Quarter 2024 Financial Results

August 8, 2024 | globenewswire.com

Synlogic Inc.

July 21, 2024 | wsj.com

Synlogic Inc SYBX

July 21, 2024 | morningstar.comM

The Summer Stock Exodus: 3 Companies to Ditch Before the Heat Hits

May 23, 2024 | investorplace.com

Hold Rating Maintained for Synlogic Amidst Setbacks and Financial Uncertainties

May 16, 2024 | markets.businessinsider.com

SYBX Stock Earnings: Synlogic Misses EPS, Misses Revenue for Q1 2024

May 14, 2024 | investorplace.com

Synlogic, Inc.: Synlogic Reports First Quarter 2024 Financial Results

May 14, 2024 | finanznachrichten.de

Synlogic Flat on Q1 Numbers

May 14, 2024 | baystreet.ca

Synlogic Reports First Quarter 2024 Financial Results

May 14, 2024 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

OGEN, SYBX, PMN, and CMMB Company Descriptions

Chemomab Therapeutics NASDAQ:CMMB

$0.89 +0.01 (+0.56%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$0.87 -0.02 (-2.25%)

As of 08/22/2025 07:59 PM Eastern

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Oragenics NYSE:OGEN

$1.11 +0.03 (+2.78%)

Closing price 08/22/2025 03:58 PM Eastern

Extended Trading

$1.10 -0.01 (-0.45%)

As of 08/22/2025 07:53 PM Eastern

Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

Promis Neurosciences NASDAQ:PMN

$0.54 -0.01 (-2.39%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$0.54 +0.00 (+0.39%)

As of 08/22/2025 07:18 PM Eastern

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Synlogic NASDAQ:SYBX

$1.46 +0.06 (+4.29%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.46 0.00 (-0.34%)

As of 08/22/2025 04:10 PM Eastern

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time